Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,195,232
  • Shares Outstanding, K 231,809
  • Annual Sales, $ 258,220 K
  • Annual Income, $ -28,240 K
  • 60-Month Beta 0.43
  • Price/Sales 8.65
  • Price/Cash Flow 185.17
  • Price/Book 13.97
Trade ADMA with:

Options Overview Details

View History
  • Implied Volatility 27.64% ( -5.13%)
  • Historical Volatility 71.00%
  • IV Percentile 1%
  • IV Rank 4.63%
  • IV High 171.68% on 04/05/24
  • IV Low 20.64% on 02/13/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 351
  • Volume Avg (30-Day) 1,288
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 21,520
  • Open Int (30-Day) 19,804

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.08
  • Number of Estimates 2
  • High Estimate 0.08
  • Low Estimate 0.08
  • Prior Year -0.02
  • Growth Rate Est. (year over year) +500.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.26 +52.72%
on 04/25/24
9.77 -2.15%
on 05/22/24
+3.10 (+47.99%)
since 04/24/24
3-Month
5.08 +88.19%
on 02/29/24
9.77 -2.15%
on 05/22/24
+4.30 (+81.75%)
since 02/23/24
52-Week
3.06 +212.42%
on 10/23/23
9.77 -2.15%
on 05/22/24
+5.53 (+137.22%)
since 05/24/23

Most Recent Stories

More News
Adma Biologics: Q1 Earnings Snapshot

Adma Biologics: Q1 Earnings Snapshot

ADMA : 9.56 (+0.95%)
Chart of the Day: ADMA Biologics - Hitting New Highs

The Chart of the Day belongs to the biomedical company ADMA Biologics (ADMA) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals,...

ADMA : 9.56 (+0.95%)
Adma Biologics: Q4 Earnings Snapshot

Adma Biologics: Q4 Earnings Snapshot

ADMA : 9.56 (+0.95%)
Why Adma Biologics Stock Crushed the Market on Friday

The network of FDA-approved collection facilities continues to grow.

ADMA : 9.56 (+0.95%)
Why Adma Biologics Was Trouncing the Market Today

The company beat analyst estimates for both revenue and profitability, and raised revenue guidance.

ADMA : 9.56 (+0.95%)
Adma Biologics: Q3 Earnings Snapshot

Adma Biologics: Q3 Earnings Snapshot

ADMA : 9.56 (+0.95%)
Why Shares of ADMA Biologics Are Climbing Thursday

The company, which focuses on infectious diseases, reported its second-quarter earnings on Wednesday after the markets closed.

ADMA : 9.56 (+0.95%)
Adma Biologics: Q2 Earnings Snapshot

Adma Biologics: Q2 Earnings Snapshot

ADMA : 9.56 (+0.95%)
Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates

Adma Biologics (ADMA) delivered earnings and revenue surprises of 40% and 10.84%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ADMA : 9.56 (+0.95%)
SABS : 2.72 (+5.02%)
Adma Biologics: Q1 Earnings Snapshot

Adma Biologics: Q1 Earnings Snapshot

ADMA : 9.56 (+0.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 10.03
2nd Resistance Point 9.88
1st Resistance Point 9.72
Last Price 9.56
1st Support Level 9.42
2nd Support Level 9.27
3rd Support Level 9.11

See More

52-Week High 9.77
Last Price 9.56
Fibonacci 61.8% 7.21
Fibonacci 50% 6.41
Fibonacci 38.2% 5.62
52-Week Low 3.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar